Corporate ProfileNantHealth is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth‘s unique systems-based approach to personalized healthcare integrates novel diagnostics with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine. In addition, NantHealth’s adaptive learning system, CLINICS, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time.
Stock Quote NH (Common Stock) $0.69 - 0.03 (0.00%)
Today's Open$0.75
Previous Close$0.69
Data as of 01/17/19 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NH.O.  Currently trading at $0.69 with a 52 week high of $4.00 and a 52 week low of $0.48.
Recent News

January 04, 2019

NantCell Announces New Celgene Investment

Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7thSecond Round Crossover Funding Brings Celgene's Investment to $105M in NantCell Valued at $4 BillionCurrently Enrolling Patients in Advanced Stage Trials in 15 Indications for Registration IntentDeep Pipeline Of 28 Unique Molecules With 14 First in Human Studies in Over 1,000 Patients to DateLos Angeles, CA, January 4, 2019 – NantCell and it's founder Dr. Patrick Soon-Shiong announce...

Read More >

December 03, 2018

NantHealth® to Present New Research Findings at the San Antonio Breast Cancer Symposium

Topics to include DNA and RNA profiling and next-generation sequencing of tumors SAN ANTONIO--(BUSINESS WIRE)--Dec. 3, 2018-- Significant developments in breast cancer research will be presented by NantHealth (NASDAQ: NH) at the San Antonio Breast Cancer Symposium this week. NantHealth, a leader in breakthrough cancer research and solutions to improve patient care and lower healthcare costs, will discuss the findings of three investigations, w...

Read More >

November 15, 2018

NantHealth Reports 2018 Third-Quarter Financial Results

Total Revenue in Q3 was $22.3 Million SaaS revenue of $15.9 million in Q3, up 5% from $15.2 million in prior year Q3 Enhanced efficiencies continued to drive reduced operating expenses and improved adjusted bottom line results Sequencing and Molecular Analysis, 930 total tests ordered in Q3, including 461 GPS Cancer® and 469 Liquid GPS® Tests...

Read More >

Upcoming Events
There are currently no events scheduled.